Whether it is extended or localized and regardless of the level of severity, Dermablend will even out the skin tone without blocking the pores.
Thanks to its high professional coverage, malleable and long-lasting, it recreates healthy and beautiful skin. Suitable for all skin types, even sensitive.
You can be just as beautiful on the outside as on the inside.
Dermablend was created in 1981 by an American dermatologist, Dr. N. Craig Roberts, whose wife suffered from facial vitiligo (depigmentation of the skin).
This unique technology offers extreme coverage combined with optimum tolerance to instantly and perfectly correct cutaneous flaws, even the most severe.
In 2003, Vichy Laboratories decided to launch the brand to benefit women and men all over the world.
Dermablend’s mission: to improve the quality of life for women and men.
16 hours coverage
« Bare skin feel » finish
Available in 5 shades
14 hours coverage
No mask effect
Available in 7 shades
are affected by a
visible skin imperfection.
are aware of being perceived
differently by others.
More than 1/3 lose confidence in themselves and feel destabilized by negative thoughts and questions*.
With Dermablend, Vichy Laboratories offers a solution that masks the appearance of skin imperfections, regardless of their severity. As a result this improves the patients’ self-esteem and well-being.
A study on 63 women showed the capacity for Dermablend to increase a woman's quality of life:
4 surveys** were conducted before and during the application of Dermablend in order to evaluate 4 different influencing aspects of their skin pathology on their quality of life.
With Dermablend, patients think less about their imperfections. The state of the skin has a significant impact on increased self-esteem and social interactions.
these improvements continue to be stable. Dermablend has a beneficial influence on a patient’s quality of life.
* Source: test conducted by dermatologists in November 2002 on 57 women suffering from major cutaneous imperfections.
** This study used the following surveys: Skindex-16 to evaluate the frequency at which the patient experienced the pathology in their lives, the QSVP to evaluate the frustration of the patient with regard to the pathology, the DLQI to evaluate the intensity of the influence of the pathology on the patient’s quality of life and the FNE to evaluate the influence of the disease on interpersonal relationships (and also on self-confidence).